A partnership between German and US companies aims to develop gene therapies for neurodegenerative diseases that would cross the blood-brain barrier and deliver therapeutic agents to the brain.
The collaboration is between Sirion Biotech GmbH, which specialises in viral vector technologies for gene and cell therapies, and Denali Therapeutics Inc, a developer of treatments for diseases of the central nervous system.